-+ 0.00%
-+ 0.00%
-+ 0.00%

Oragenics Regains Nasdaq Compliance

Benzinga·10/21/2025 12:01:43
Listen to the news

Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, announced today that it has regained full compliance with NYSE American's continued listing standards and is positioning the Company to focus exclusively on advancing its lead clinical program.